HOUSE 2339116th CongressReceived in the Senate and Read twice and referred to the Committee on Finance.

Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020

Last Action: 3/2/2020

Actions

2020-03-02Received in the Senate and Read twice and referred to the Committee on Finance.
2020-02-28Motion to reconsider laid on the table Agreed to without objection.
2020-02-28On passage Passed by the Yeas and Nays: 213 - 195 (Roll no. 78). (text: CR H1257-1262)
2020-02-28Passed/agreed to in House: On passage Passed by the Yeas and Nays: 213 - 195 (Roll no. 78).
2020-02-28On motion to recommit with instructions Failed by the Yeas and Nays: 187 - 220 (Roll no. 77).
2020-02-28The previous question on the motion to recommit with instructions was ordered without objection.
2020-02-28Floor summary: DEBATE - The House proceeded with 10 minutes of debate on the Walden motion to recommit with instructions. The instructions contained in the motion seek to require the bill to be reported back to the House with an amendment to insert a new title at the end of the bill, "Born-Alive Abortion Survivors Protection."
2020-02-28Mr. Walden moved to recommit with instructions to the Committee on Energy and Commerce. (text: CR H1286-1287)
2020-02-28Considered as unfinished business. (consideration: CR H1286-1289)
2020-02-28POSTPONED PROCEEDINGS - Pursuant to clause 1(c) of Rule XIX, further proceedings on H.R. 2339 were postponed.
2020-02-28The previous question was ordered pursuant to the rule.
2020-02-28DEBATE - The House proceeded with 90 minutes of debate on H.R. 2339.
2020-02-28Rule provides for consideration of H.R. 2339 with 1 hour and 30 minutes of general debate. Motion to recommit with or without instructions allowed.
2020-02-28Considered under the provisions of rule H. Res. 866. (consideration: CR H1257-1286)
2020-02-27Rule H. Res. 866 passed House.

Showing 15 of 20 actions. Full history on Congress.gov.

CRS Summary

As of 2020-02-28 (53)

Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020

This bill revises requirements related to the safety, sale, and advertisement of tobacco products, including electronic nicotine delivery systems (e.g., e-cigarettes, e-hookah, e-cigars, and vape pens).

Among other requirements, the bill

requires the Food and Drug Administration (FDA) to implement regulations to require color graphics on the labeling of cigarette packages, depicting the negative health consequences of smoking;
requires the FDA to apply regulations on tobacco products to all tobacco products, including e-cigarettes;
generally prohibits the retail online sale of tobacco products, including electronic nicotine delivery systems;
prohibits flavors other than tobacco in a tobacco product;
prohibits the use of flavored products in an electronic nicotine delivery system, except in specified circumstances;
increases the user fees that the FDA collects from manufacturers and importers;
directs the FDA to regulate products containing nicotine not made or derived from tobacco plants (including nicotine from chemical synthesis, recombinant genetic technology, or extraction from non-tobacco plants);
imposes an excise tax on nicotine that has been extracted, concentrated, or synthesized;
provides funding through FY2025 to support public education regarding tobacco regulation, public awareness regarding the harms associated with tobacco use, outreach to medically underserved communities regarding tobacco-use prevention and cessation, research grants related to tobacco-use prevention and cessation, and grants to health centers for tobacco-use cessation treatment;
establishes and provides funding through FY2025 for a demonstration grant program to develop strategies for smoking cessation (including of the use of menthol-flavored tobacco products) in medically underserved communities;
beginning in 2024, waives coinsurance under Medicare for colorectal-cancer screening tests;
specifies that a health insurance plan may still be treated, for certain tax-deduction purposes, as a high-deductible plan even if it does not have a deductible for certain inhalers or nebulizers;
exempts certain cigars from premarket review requirements;
increases civil penalties for certain violations of restrictions on the sale of tobacco products; and
requires the Government Accountability Office to study e-cigarettes.

Cosponsors (20)

Donna Shalala (D-FL)
BOBBY RUSH (D-IL)
BARBARA LEE (D-CA)
John Sarbanes (D-MD)
Lauren Underwood (D-IL)
Lisa Blunt Rochester (D-DE)
Debbie Mucarsel-Powell (D-FL)
JANICE SCHAKOWSKY (D-IL)
Joe Neguse (D-CO)
Mike Quigley (D-IL)
Thomas Suozzi (D-NY)
TIM RYAN (D-OH)
Jamie Raskin (D-MD)
Paul Tonko (D-NY)
Steve Cohen (D-TN)
ELIOT ENGEL (D-NY)
Terri Sewell (D-AL)
Joseph Kennedy (D-MA)
Chellie Pingree (D-ME)
Debbie Wasserman Schultz (D-FL)

Subjects

Administrative law and regulatory procedures
Cancer
Cardiovascular and respiratory health
Child health
Civil actions and liability
Congressional oversight
Consumer affairs
Department of Health and Human Services
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Drug, alcohol, tobacco use
Food and Drug Administration (FDA)
Government information and archives
Government studies and investigations
Health care costs and insurance
Health care coverage and access
Health facilities and institutions
Health information and medical records
Health programs administration and funding

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.